

Sun Pharmaceutical Industries Limited

Sun House, Plot No. 201 B/1,
Western Express Highway, Goregaon (E),
Mumbai – 400 063, Maharashtra, INDIA.
Tel. : (91-22) 4324 4324
Fax : (91-22) 4324 4343
Website: www.sunpharma.com
CIN: L24230GJ1993PLC019050



May 10, 2021

To,
National Stock Exchange of India Ltd.,
Exchange Plaza, 5th Floor,
Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra (East), Mumbai – 400 051.

BSE Ltd.,
Market Operations Dept.
P. J. Towers,
Dalal Street,
Mumbai - 400 001.

NSE Code: SUNPHARMA

BSE Code: 524715

Dear Sir/ Madam,

Sub: Notice of Board Meeting for consideration and approval of Audited Standalone and Consolidated Financial Results of the Company for the fourth quarter and year ended on March 31, 2021 and to consider recommendation of final dividend for the year ended March 31, 2021.

This is to inform you that the meeting of the Board of Directors of the Company will be held on Thursday, May 27, 2021, inter alia, to transact the following business:

- (i) To consider and approve Audited Standalone and Consolidated Financial Results of the Company for the fourth quarter and year ended March 31, 2021.
- (ii) To consider recommendation of final dividend for the year ended March 31, 2021 subject to the approval of the shareholders at the ensuing 29th Annual General Meeting.

Further, kindly note that pursuant to the Company's Code of Conduct for Prevention of Insider Trading, the window closure for trading by Designated Persons, commenced on April 01, 2021, and shall end on May 29, 2021 i.e. after 48 hours of the declaration of financial results of the Company on May 27, 2021.

This is for your information and dissemination.

Thanking you,

Yours faithfully,

For Sun Pharmaceutical Industries Limited

Ashok I. Bhuta
Compliance Officer